Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FOLFOX6 or FOLFIRI plus sorafenib versus placebo in second-line metastatic colorectal cancer
2008-000803-26Phase 2Terminated
- Sponsor
- AIO-Studien-gGmbH
- Start
- Dec 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in metastatic colon cancer (mCRC) comparing Sorafenib + FOLFOX6 or FOLFIRI with Placebo + FOLFOX6 or FOLFIRI (2 arms). Primary endpoint: Progression-free survival. Started Dec 2008; status: terminated.
02
Drugs
sorafenib
03
Conditions
metastatic colon cancer (mCRC)
Beyond the preview
Go deeper on 2008-000803-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-000803-26.